The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

A.N. Boyko

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

V.M. Alifirova

Siberian State Medical University

I.G. Lukashevich

Orden of the Red Banner of Labor City Clinical Hospital No. 1

Z.A. Goncharova

Rostov State Medical University

I.V. Greshnova

Regional Clinical Hospital

L.G. Zaslavsky

Pavlov First Saint Petersburg State Medical University

S.V. Kotov

Vladimirsky Moscow Regional Research Clinical Institute

N.A. Malkova

State Novosibirsk Regional Clinical Hospital;
Novosibirsk State Medical University

G.N. Mishin

Pyatigorsk City Clinical Hospital No. 2

E.V. Parshina

Semashko Nizhny Novgorod Regional Clinical Hospital

I.Ye. Poverennova

Seredavin Samara Regional Clinical Hospital

L.N. Prakhova

N. Bechtereva Institute of the Human Brain

S.A. Sivertseva

Medical and Sanitary unit «Neftyanik»

I.V. Smagina

Altai State Medical University

N.A. Totolyan

Academician I.P. Pavlov First Saint Petersburg State Medical University

Yu.V. Trinitatsky

Rostov Regional Clinical Hospital

T.N. Trushnikova

Wagner Perm State Medical University

F.A. Khabirov

City Clinical Hospital No. 7;
Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuing Professional Education

S.G. Shchur

Municipal Filatov Clinical Hospital No. 15

A.V. Artemyeva

AO BIOCAD

D.D. Bolsun

AO BIOCAD

A.V. Zinkina-Orikhan

AO BIOCAD

Yu.N. Linkova

AO BIOCAD

Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2

Authors:

A.N. Boyko, V.M. Alifirova, I.G. Lukashevich, Z.A. Goncharova, I.V. Greshnova, L.G. Zaslavsky, S.V. Kotov, N.A. Malkova, G.N. Mishin, E.V. Parshina, I.Ye. Poverennova, L.N. Prakhova, S.A. Sivertseva, I.V. Smagina, N.A. Totolyan, Yu.V. Trinitatsky, T.N. Trushnikova, F.A. Khabirov, S.G. Shchur, A.V. Artemyeva, D.D. Bolsun, A.V. Zinkina-Orikhan, Yu.N. Linkova

More about the authors

Views: 1884

Downloaded: 5


To cite this article:

Boyko AN, Alifirova VM, Lukashevich IG, Goncharova ZA, Greshnova IV, Zaslavsky LG, Kotov SV, Malkova NA, Mishin GN, Parshina EV, Poverennova IYe, Prakhova LN, Sivertseva SA, Smagina IV, Totolyan NA, Trinitatsky YuV, Trushnikova TN, Khabirov FA, Shchur SG, Artemyeva AV, Bolsun DD, Zinkina-Orikhan AV, Linkova YuN. Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2023;123(4):37‑47. (In Russ.)
https://doi.org/10.17116/jnevro202312304137

Recommended articles:
A clinical case of multiple scle­rosis with an episode of schi­zophrenia-like syndrome. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2023;(4):120-124
BDNF gene RS6265 poly­morphism in patients with multiple scle­rosis of Tomsk region. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2023;(5):160-164
New neuroimaging methods in asse­ssing the acti­vity of neuroinflammation in multiple scle­rosis. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2023;(7-2):8-14
Changes in venous circulation in patients with multiple scle­rosis. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2023;(7-2):22-28
Rela­tionship of patients with multiple scle­rosis to vaccination against COVID-19. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2023;(7-2):29-33

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation



We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.